LFCR LIFECORE BIOMEDICAL, INC. DE
8-K Current Report
Filed: March 16, 2026
Health Care
Pharmaceutical PreparationsLIFECORE BIOMEDICAL, INC. DE (LFCR) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full transition period results ending Dec 31, 2025 now reported by Lifecore Biomedical (LFCR)
- • Press release (Exhibit 99.1) contains full financial details — primary source for revenue, margins, and earnings figures
Item 7.01 · Regulation FD Disclosure
- • Investor presentation published March 16, 2026 on LFCR's website — full details in Exhibit 99.2
- • Reg FD disclosure ensures simultaneous public access; content may include guidance, strategy, or financial updates material to valuation
Other LIFECORE BIOMEDICAL, INC. DE 8-K Filings
Get deeper insights on LIFECORE BIOMEDICAL, INC. DE
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.